What Changed
- Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- A Fidelity pool has a 6% interest in Odyssey Therapeutics (ODTX), where FMR also reports ownership.
- Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
Price Move History
- Daily moves over 5%
- 30 136 sessions, May 8, 2026 to November 19, 2026
- Largest daily move
- -13% close of October 6, 2026
- 1-month change
- +1.3% closing prices, October 19, 2026 to November 19, 2026
Company Description
Odyssey Therapeutics (NASDAQ: ODTX) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $881.6M.
ODTX has gained 1.3% over the past month. The last closing price was $18.34.
This page collects what Stock Titan holds for ODTX, including price data, latest news, SEC filings, upcoming events, and short interest trends.
Stock Performance
Odyssey Therapeutics (ODTX) closed at $18.34 on November 19, 2026. Over the past month, the price has gained 1.3%.
ODTX Metrics & Rankings
Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Odyssey Therapeutics has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, clinical trial, conferences, AI. View all ODTX news →
SEC Filings
Odyssey Therapeutics has filed 10 recent SEC filings, including 6 Form 8-K, 3 Form 10-Q, 1 Form SCHEDULE 13G/A. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ODTX SEC filings →
Financial Highlights
Odyssey Therapeutics has not filed a full fiscal year of results yet, so there are no annual figures to show here, and the quarterly figures it has reported so far are on its financials page.
Upcoming Events
OD-002 trial start
Preclinical studies completion
OD-001 trial results
Phase 2 topline results
Topline induction results
Odyssey Therapeutics has 5 upcoming scheduled events. The next event, "OD-002 trial start", is expected in H1 2027. Investors can track these dates to stay informed about potential catalysts that may affect the ODTX stock price.
Short Interest History
Short interest in Odyssey Therapeutics (ODTX) currently stands at 3.3 million shares, up 2.0% from the previous reporting period, representing 8.9% of the float. Since May 2026, short interest has increased by 3770.1%.
Days to Cover History
Days to cover for Odyssey Therapeutics (ODTX) currently stands at 15.4 days, up 24.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since May 2026, the figure has increased by 1443%. Across the settlements charted above, it has ranged from 1.0 to 18.7 days.
ODTX Company Profile & Sector Positioning
Odyssey Therapeutics (ODTX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing ODTX often look at related companies in the same sector, including Prime Medicine, Inc. (PRME), Aktis Oncology, Inc. (AKTS), City Therapeutics, Inc. (CTY), Corvus Pharmaceuticals, Inc. (CRVS), and MeiraGTx Holdings plc (MGTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ODTX's relative position within its industry.